Sarah A. Solomon

Sarah A. Solomon is a partner in the firm’s Life Sciences group. She currently serves on the firm’s Executive Committee and as a Co-Chair of Women@Goodwin.

Sarah represents biotechnology, pharmaceutical and other life sciences companies in connection with their intellectual property, commercial, and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions; research, development, manufacturing, and commercial relationships; and mergers and acquisitions. Sarah also counsels clients in connection with international transactions in North America, South America, Europe, and Asia.

Strategic Alliances and Collaborations

• ADARx on its license and collaboration agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease for $335 million upfront
• Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment
• Alnylam Pharmaceuticals in its license and collaboration agreement with PeptiDream to discover and develop peptide-siRNA conjugates for targeted delivery of RNAi therapeutics, with a potential deal value of $2.2 billion in milestones
• Alnylam Pharmaceuticals in its collaboration with Regeneron Pharmaceuticals for new RNA interference therapeutics focused on ocular and central nervous system diseases with deal value up to $1 billion
• Arrakis Therapeutics in its strategic collaboration and license agreement with Roche for the discovery of RNA-targeted small molecule (rSM) drugs against a broad set of targets across all of Roche’s research and development areas, for $190 million upfront
• Ascidian Therapeutics on its research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases, with a potential deal value of $1.8 billion in milestones
• Blueprint Medicine in its worldwide collaboration with Roche for up to five small molecule kinase therapeutics for cancer immunotherapy; upfront of $45 million with total deal value of up to $965 million
• BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks
• Deep Apple Therapeutics in a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases with deal value up to $812 million
• ImmuNext in its exclusive, worldwide license with Sanofi to develop and commercialize a CD40L monoclonal antibody for use in autoimmune diseases, with potential deal value of up to $500 million, plus royalties
• Immunometabolism Development Company in a licensing transaction with a global pharmaceutical company, with potential deal value of up to $605 million
• Jnana Therapeutics in its second collaboration and license agreement with Roche for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases, with potential deal value of over $2 billion
• Kymera Therapeutics in its strategic collaboration with Vertex to advance small molecule protein degraders against multiple biological targets, with potential deal value in excess of $1 billion
• Kymera Therapeutics in its strategic partnership with Sanofi to advance novel protein degrader therapies, with potential deal value of over $2 billion, plus royalties
• Kymera Therapeutics in its exclusive option and license agreement with Gilead Sciences, Inc. to accelerate the development and commercialization of a novel molecular glue degrader, with potential deal value of up to $750 million
• Moderna in its supply agreements for Moderna’s COVID-19 vaccine with governments around the world
• Moderna in its strategic partnerships with the Australian Government and Canadian Government
• Moderna in its collaboration with Merck for the development and commercialization of mRNA cancer vaccines
• Nimbus Therapeutics in its research collaboration and license agreement with a global pharmaceutical company, with deal value of up to $496 million, plus royalties
• Oak Hill Bio in an exclusive license agreement with Roche to obtain global rights for rugonersen
• Obsidian Therapeutics in its strategic collaboration with Celgene to develop novel, regulated cell therapies using Obsidian’s destabilizing domain technology
• Radius Health in a global license agreement with the Menarini Group for the development and commercialization of Elacestrant, with a potential deal value of up to $350 million plus royalties
• Remedium Bio, Inc. in its multi-target research and development collaboration with Eli Lilly and Company to develop and commercialize gene therapies for obesity and Type 2 diabetes
• Replicate Bioscience on a multi-year research collaboration with Novo Nordisk for up to $550 million
• Scholar Rock in its strategic collaboration with Gilead to develop TGFβ inhibitors with potential total deal value of up to $1.5 billion
• Schrödinger, Inc. in its collaboration and license agreement with Bristol Myers Squibb to discover, develop and commercialize therapeutics in multiple disease areas, with potential deal value of $2.7 billion, plus royalties
• Schrödinger, Inc. in its collaboration with Zai Lab on a global R&D program in oncology
• Tessera Therapeutics on an agreement with Bill & Melinda Gates Foundation to jointly fund the company’s in vivo program for sickle cell disease for up to $50 million
• Wave Life Sciences in its strategic collaboration with GSK to advance oligonucleotide therapeutics, with potential deal value of over $3.3 billion
• Wave Life Sciences in its global strategic collaboration with Takeda for nucleic acid therapies for CNS disorders, with potential deal value of over $2 billion

M&A

• Anthos Therapeutics in its acquisition by Novartis for up to $3.1 billion
• Blueprint Medicines Corporation in its acquisition by Sanofi for up to $9.5 billion
• BlueRock Therapeutics in its sale to Bayer AG for up to $1 billion
• Nimbus in its sale of Nimbus Apollo and its Acetyl-CoA Carboxylase (ACC) inhibitor program to Gilead Sciences for $400 million and up to an additional $800 million in development milestone payments
• Nimbus in its sale of Nimbus Lakshmi and its Tyk2 inhibitor program to Takeda for $4 billion upfront and up to $2 billion in commercial-related milestone payments
• Noria Therapeutics and PSMA Therapeutics in their sale to Bayer
• Promedior in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $1.25 billion
• TARIS Biomedical in the sale of its lead product LiRIS to Allergan for a total potential deal value in excess of $580 million
• TARIS Biomedical in its acquisition by Johnson & Johnson
• Vigil Neuroscience in its acquisition by Sanofi for $470 million and contingent value rights
• ZOLL Medical in its sale to Asahi Kasei for $2.2 billion

Sarah has been recognized as a leading life sciences attorney by Chambers USA, The Best Lawyers in America, IAM Patent 1000, The International Who’s Who of Life Sciences Lawyers (Transactional), The Legal 500 United States (Intellectual Property - Patents: Licensing), and LMG Life Sciences (Licensing & Collaboration, Mergers & Acquisitions). In 2020, Sarah was nominated by LMG Life Sciences as “Licensing & Collaboration Attorney of the Year.” Sarah was a leader of the Moderna/Goodwin team recognized by The American Lawyer as the Best Client-Law Firm Team of 2021.

Sarah’s presentations and publications include:

• “Model Term Sheet for University Life Science Startup License,” Consortium of Academic Institutions, Venture Capital Firms and Life Sciences Lawyers, November 21, 2022
• Speaker, “Biopharma Deal Maker’s Approach to Maximizing Strategic Partnerships,” Goodwin and Locust Walk Live Webinar, May 7, 2020
• Co-Author, “Qualifying for Immunity Under the U.S. Prep Act During COVID-19,” Goodwin Client Alert, April 21, 2020
• “Structuring Life Sciences Partnering and M&A Agreements,” New York Healthcare + CLE Day, October 24, 2019